SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coya Therapeutics, Inc. is a clinical-stage biotechnology company which engages in developing proprietary medicinal products to modulate the function of regulatory T cells. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Coya Therapeutics Inc

Fueled by promising trial results and a strategic partnership with Dr. Reddy's, Coya is trending as the community focuses on its potential to disrupt the neurodegenerative disease space. Discussions revolve around the upcoming Alzheimer's data and the ALS trial, with many speculating about a potential acquisition. The company's novel approach and strong financial position are also driving bullish sentiment.

Targa Resources Corp. engages in the business of gathering, compressing, treating, processing, transporting, and purchasing and selling natural gas. It operates through the following segments: Gathering and Processing, and Logistics and Transportation, and Other. The Gathering and Processing segment includes assets used in the gathering, and purchase and sale of natural gas produced from oil and gas wells. The Logistics and Transportation segment refers to the activities and assets necessary to convert mixed natural gas liquids (NGLs) into NGL products. The Other contains the results of commodity derivative activity mark-to-market gains and losses related to derivative contracts. The company was founded on October 27, 2005 and is headquartered in Houston, TX.

Targa Resources Corp

Targa Resources is trending due to its upcoming inclusion in the S&P 500, replacing Nielsen Holdings. The community is discussing the implications of this move and the company's overall strength in the energy sector. Bullish sentiment is fueled by analyst ratings and potential benefits from increased natural gas demand and strategic positioning in the Permian Basin.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynex Capital is trending as investors discuss its attractive monthly dividend and potential entry points, with some weighing it against similar REITs. Community members are highlighting the company's consistent dividend payments and solid management team. Broader market volatility and interest rate trends appear to be influencing discussions around DX.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending amid fluctuating community sentiment, with some traders betting on a pump while others express frustration over recent price action and dilution concerns. Discussions include potential DeFi integrations, comparisons to AAVE, and speculation about the Compound Foundation's financial health. Community members are closely watching BTC and ETH movements for potential market cues.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

MOS is trending due to a recent announcement regarding production interruptions in potash and phosphate, impacting sales volume guidance and spurring community discussion around its effect on the stock. Despite the negative news, some investors view the dip as a buying opportunity, citing the company's strong underlying fundamentals, value, and dividend. Community members also mentioned the potential for long-term gains and a possible rotation into the agriculture sector.

Function is building the financial infrastructure that makes Bitcoin productive, unlocking yield, liquidity, and capital efficiency for holders across DeFi and traditional finance. FBTC turns Bitcoin into an asset that works.  FBTC represents the first omnichain Bitcoin yield asset, enabling BTC holders to participate in structured, risk-managed and programmatic yield strategies. FBTC is fully backed on a 1:1 basis with BTC, Bitcoin Reserve Address List is public and can be verified at any time. FBTC combines the security of Bitcoin reserves with the flexibility of smart contracts, creating a secure and efficient bridge between the Bitcoin network and modern DeFi protocols.  FBTC turns idle BTC into a functional and productive asset. The primary purpose of FBTC is to bring native Bitcoin liquidity into DeFi. Enabling Bitcoin holders to access a wide range of yield generating strategies, without having to sell their BTC. This not only enhances the utility of BTC but also allows holders to earn returns on their assets, making FBTC a powerful tool for maximizing the potential of Bitcoin in the DeFi ecosystem

Function ƒBTC

Function BTC ($FBTC) is trending as the community discusses recent ETF outflows and potential market pullbacks affecting Bitcoin. Optimists view any dip as a buying opportunity, drawing parallels to past recoveries of major tech stocks, while others express concern about macro factors and potential bear cycles. Community members are weighing the impact of potential rate cuts, crypto bills, and the possibility of a Santa Claus rally.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending due to positive Phase 3 acne trial results, sparking community excitement about its potential in the Chinese market and a new mechanism of action. Community members are actively discussing the undervaluation of the stock, potential buyout scenarios, and upcoming catalysts including the KOL event next week. Some are concerned about the absence of news on the mash program and the need for a funding partner.

Direxion Shares ETF Trust - Direxion Daily Homebuilders & Supplies Bull 3X Shares

Direxion Daily Homebuilders & Supplies Bull 3X Shares

The Direxion Daily Homebuilders & Supplies Bull 3X Shares ($NAIL) is trending as traders discuss potential entry points based on technical indicators like falling wedge patterns and RSI levels, while some express hesitancy to invest. Community members are also weighing the ETF's outlook against broader market factors, including interest rate cut expectations and housing market data. Bullish sentiment anticipates momentum to continue into the spring, while bearish viewpoints cite concerns about a potential dip into the $30s over the winter.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB is trending as community members highlight its potential as the "new BTC" and its association with the ICP ecosystem, with some suggesting it could outperform ICP. Community discussions also revolve around upcoming halving events and its listing on new platforms like Coinbase, increasing public awareness.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending as investors assess its potential in the AI-driven data cloud sector, particularly after recent partnerships and analyst upgrades. Community discussions revolve around its long-term growth prospects and ability to maintain its competitive edge against major players. Bullish sentiment seems to be building around the stock's technical setup and potential for further upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of "Moderate Buy" by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One...

Coya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan Capital

Chardan Capital restated a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Friday...

Coya Therapeutics (NASDAQ:COYA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Coya Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Coya Therapeutics (NASDAQ:COYA) Stock Price Expected to Rise, BTIG Research Analyst Says

BTIG Research increased their price objective on Coya Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday...

Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $15.00 price target on shares of Coya Therapeutics in a research note on Wednesday...

Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Misses Estimates By $0.12 EPS

Coya Therapeutics (NASDAQ:COYA - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus...

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced...

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

COYA
Coya Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest COYA News

COYACoya Therapeutics Inc